|

Analysis of the Role of IgE Proteoforms in Health and Disease

RECRUITINGSponsored by KU Leuven
Actively Recruiting
SponsorKU Leuven
Started2025-01-01
Est. completion2029-01-01
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT07328178

Summary

The goal of this observational study is to evaluate the role of IgE proteoforms in healthy volunteers and in patients with type I allergy, patients with chronic spontaneous urticaria, patients with a recent history of anaphylaxis, patients with mastocytosis, patients with hereditary alpha tryptasemia, patients with X-linked agammaglobulinemia (XLA), and patients undergoing desensitization for venom or medication allergy.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

* CSU and type I allergic diseases (including anaphylaxis and desensitization), atopic dermatitis, mastocytosis, XLA and HaT (informed consent, age: any available adult subject, gender: any available subject, clinical phenotype and specific information about the allergy (e.g. severity, medication, medical history, laboratory testing)
* Healthy controls (informed consent, age matched to the allergic patients, gender matched to the allergic patients, patient-reported symptoms related to allergy to aeroallergens, food, drugs, hymenoptera venom, CSU)

Exclusion Criteria:

* Absence of informed consent
* Age \< 18 years old

Conditions10

AnaphylaxisCancerChronic Spontaneous Urticaria (CSU)Healthy ControlHereditary Alpha-TryptasemiaMastocytosisMedication AllergyType I AllergyVenom AllergyX-linked Agammaglobulinaemia

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.